DOSING & PREPARING KRYSTEXXA
Review dosing and preparation instructions for KRYSTEXXA to prepare for your patient’s first infusion.
RECOMMENDED KRYSTEXXA DOSING REGIMEN
The recommended dose and regimen of KRYSTEXXA for adult patients is 8 mg (uricase protein) given as an intravenous infusion every two weeks. The optimal treatment duration with KRYSTEXXA has not been established.
KRYSTEXXA is a clear, colorless, sterile 8 mg/mL solution of pegloticase in a 2 mL single-use vial, expressed as amounts of uricase protein. KRYSTEXXA must be diluted prior to use.
PREPARING KRYSTEXXA FOR INFUSION
Visually inspect vial for particulate matter and ensure solution is clear and colorless
Using aseptic technique, withdraw 1 mL into a sterile syringe and inject into a 250 mL bag of normal or half-normal saline.
Gently mix the bag by inverting several times and discard any unused portion of the remaining product. Do not shake.
- If not administered immediately, it is recommended that the diluted solution should be stored in the refrigerator and away from light
Before administration, allow the diluted solution of KRYSTEXXA to reach room temperature.
- Artificial heating should not be used
- The diluted solution should be used within 4 hours
TEST FOR G6PD* DEFICIENCY PRIOR TO FIRST INFUSION
|Screening Classification Normal Quantitative Value OR Negative Qualitative Result for Deficiency||Interpretation Patient Does Not Have G6PD Deficiency||Recommendation1 Can Proceed to Treatment With KRYSTEXXA as Indicated|
|Screening Classification Low Quantitative Value OR Positive Qualitative Result for Deficiency||Interpretation Patient May Have G6PD Deficiency†||
Do Not Administer KRYSTEXXA to
Patients With G6PD Deficiency
If you have general questions regarding screening for G6PD deficiency, please call Medical Information at 1-866-479-6742
*KRYSTEXXA is contraindicated for patients with G6PD deficiency. G6PD deficiency is an abnormally low level of glucose-6-phosphate dehydrogenase. Patients of African, Mediterranean, and Southern Asian ancestry have a higher risk of G6PD deficiency.1
†Acute hemolytic anemia, which may be the result of the patient’s medications, can produce inaccurate results. Additionally, if a patient has received a blood transfusion in the past 90 days, the transfusion could alter the test results. For either of these situations, postpone testing or consider retesting in 2 to 3 months.2,3
- KRYSTEXXA (pegloticase) [prescribing information] Horizon.
- Belfield KD, et al. Am J Health Syst Pharm. 2018;75:e69-e76.
- Minucci A, et al. IUBMB Life. 2009;61:27-34.